CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 265 resultados LastUpdate Última actualización 26/01/2021 [15:01:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 120 días/Published applications in the last 120 days



previousPage Página2 de 11 nextPage   por página


19 Sterilization apparatus having monitor for covid- 19 diffusion protection

NºPublicación: KR102193257B1 22/12/2020

Solicitante:

KSAFE [KR]

Resumen de: KR102193257B1

본 발명은 코로나 19 확산 예방을 위한 모니터가 구비된 소독장치에 관한 것이다. 본 발명은 방문자가 인적사항을 터치하여 입력할 수 있는 모니터와 상기 모니터의 하부와 결합되어 있는 상단커버와 상기 상단커버의 하부와 연결 형성되며, 전면커버와 후면커버가 서로 결합되어 이루어지는 사각 형상의 본체와 상기 전면커버에는 내부 기체를 외부로 배출되도록 하기 위해 형성되는 1개 이상의 분사구와 상기 본체의 하부를 결합하여 마감하는 트레이와 상기 트레이의 하부에는 이동을 하기 위하여 모서리 부분에 각각 결합되어 형성되는 이동수단과 상기 본체의 양측에 각각 형성되어 회동이 가능한 파지부와 상기 파지부의 하방에 형성되어 소정 공간의 수용부가 마련된 홀더부와 상기 본체의 내부에는 상기 은나노를 송풍에 의하여 상기 분사구를 통하여 외부로 분사시키는 송풍장치를 포함하는 것을 특징으로 한다.

traducir

ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR

NºPublicación: RU2738885C1 18/12/2020

Solicitante:

IVASHCHENKO ANDREJ ALEKSANDROVICH [RU]

Resumen de: RU2738885C1

FIELD: medicine; pharmaceutics.SUBSTANCE: invention relates to the field of medicine and pharmaceutics. Disclosed is the use of a pharmaceutical composition containing aprotinin as an active ingredient and excipients, as an antiviral agent for treating and preventing COVID-19.EFFECT: invention provides high antiviral activity in the treatment and prevention of COVID-19.4 cl, 4 ex

traducir

LACTOFERRIN FOR ORAL USE WITH ANTIVIRAL ACTION

NºPublicación: WO2020250209A2 17/12/2020

Solicitante:

SOFAR SPA [IT]

Resumen de: WO2020250209A2

The present invention relates to a composition comprising lactoferrin for oral use as an antiviral, preferably for use in the treatment of viral infections of the respiratory system and of symptoms or disorders deriving from, or relating to, said viral infections, preferably SARS-coronavirus viral infections (e.g. COVID-19).

traducir

2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUOROARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRO-DRUGS AND USES THEREOF

NºPublicación: WO2020252380A2 17/12/2020

Solicitante:

SOUTHERN RES INSTITUTE [US]

Resumen de: WO2020252380A2

The present disclosure is concerned with 2,4,7-substituted-7-deaza-2'-deoxy-2'- fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), 229E, NL63, OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS

NºPublicación: WO2020247665A1 10/12/2020

Solicitante:

UNIV EMORY [US]

Resumen de: WO2020247665A1

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

traducir

METABOLIC SIGNATURES ASSOCIATED WITH DIAGNOSIS, DISEASE PROGRESSION, AND IMMUNOLOGICAL RESPONSE TO TREATMENT OF PATIENTS WITH COVID-19

NºPublicación: US2020386766A1 10/12/2020

Solicitante:

METABOLOMYCS INC [US]

Resumen de: US2020386766A1

A system and method for using new biomarkers to assess individual diseases, including, but not limited to, a patient's prognosis before and/or after being diagnosed with the disease. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and/or treat various diseases, including, but not limited to, COVID-19.

traducir

PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS

NºPublicación: RU2738081C1 07/12/2020

Solicitante:

FED BYUDZHETNOE UCHREZHDENIE NAUKI GOSUDARSTVENNYJ NAUCHNYJ TSENTR VIRUSOLOGII I BIOTEKHNOLOGII VEKT [RU]

Resumen de: RU2738081C1

FIELD: biotechnology.SUBSTANCE: presented are immunogenic peptides used as a component of a vaccine composition against coronavirus infection COVID-19, having structures presented in Fig. 1. Described is a vaccine for coronavirus infection COVID-19, containing various combinations of said peptides: peptide immunogens having amino acid sequences SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5; or peptide immunogens having amino acid sequences SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6; or peptide immunogens having amino acid sequences SEQ ID NO: 4 and SEQ ID NO: 6; or peptide immunogens having amino acid sequences SEQ ID NO: 4 and SEQ ID NO: 7. Said peptide immunogens are covalently bound in the form of conjugates with a carrier protein, and the mixture of said conjugates of peptide immunogens and carrier protein is sorbed on a pharmaceutically acceptable adjuvant.EFFECT: technical result of the invention is obtaining such peptide immunogens and vaccine compositions, which carry minimally required antigenic determinants to form a specific immune response in rabbits, ferrets and hamsters and induce the protective immunity against COVID-19.9 cl, 5 dwg, 4 tbl, 7 ex

traducir

INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6

NºPublicación: RU2737799C1 03/12/2020

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE NAUKI NAUCHNYI TSENTR BIOMEDITSINSKIKH TEKH FEDE [RU]

Resumen de: RU2737799C1

FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to infectious and internal diseases, and aims to treat COVID-19. Hexapeptide of formula (I): H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof is used in the treatment of a respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, by pulmonary administration to a mammal in need thereof. Also for treating respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, using an aqueous pharmaceutical composition containing said hexapeptide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant, by pulmonary administration to a mammal in need thereof. Furthermore, a method of treating respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, involves a stage of pulmonary administration of an effective amount of said hexapeptide or its pharmaceutically acceptable salt to a mammal in need thereof.EFFECT: using the group of inventions enables providing more effective prevention, reduction or elimination of the symptoms of respiratory disease associated with IL-6, where the respiratory disease is COVID-19.9 cl, 10 ex, 6 tbl, 4 dwg

traducir

WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME

NºPublicación: WO2020240472A1 03/12/2020

Solicitante:

AYBAR ECOTECHNOLOGIES CORP [DO]

US_2020376094_A1

Resumen de: WO2020240472A1

A wide-spectrum antibacterial pharmaceutical formulation comprising lysozyme and methods of treatment to prevent or cure diseases of bacterial etiology. Excipients provided in the pharmaceutical formulation comprising lysozyme enhance the stability and efficacy of lysozyme for treating bacterial infections in a mammal. The pharmaceutical formulation comprising lysozyme does not produce harmful secondary effects on tissues or organs during prolonged treatment. The formulation can be used to treat bacterial infections of the skin, mucosal regions, and administered into the blood stream of a patient, including respiratory infections. The formulation is useful in treating bacterial infections, including those that occur along with viral infections, particularly viral infections with a respiratory component, including COVID-19.

traducir

COMPOUNDS AND THERAPEUTIC USES THEREOF

NºPublicación: WO2020243457A1 03/12/2020

Solicitante:

VIOGEN BIOSCIENCES LLC [US]

Resumen de: WO2020243457A1

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia, viral infection including SARS-CoV-2, and other complications associated with the foregoing diseases and disorders.

traducir

WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME

NºPublicación: US2020376094A1 03/12/2020

Solicitante:

AYBAR ECOTECHNOLOGIES CORP [DO]

WO_2020240472_A1

Resumen de: US2020376094A1

A wide-spectrum antibacterial pharmaceutical formulation comprising lysozyme and methods of treatment to prevent or cure diseases of bacterial etiology. Excipients provided in the pharmaceutical formulation comprising lysozyme enhance the stability and efficacy of lysozyme for treating bacterial infections in a mammal. The pharmaceutical formulation comprising lysozyme does not produce harmful secondary effects on tissues or organs during prolonged treatment. The formulation can be used to treat bacterial infections of the skin, mucosal regions, and administered into the blood stream of a patient, including respiratory infections. The formulation is useful in treating bacterial infections, including those that occur along with viral infections, particularly viral infections with a respiratory component, including COVID-19.

traducir

PERSONAL PROTECTIVE EQUIPMENT SYSTEM FOR SAFE AIR, TRAIN OR BUS TRAVEL PROTECTING AGAINST INFECTIOUS AGENTS INCLUDING NOVEL CORONAVIRUS - COVID-19

NºPublicación: US2020376305A1 03/12/2020

Solicitante:

LANG NOAH [US]

Resumen de: US2020376305A1

Aspects of the invention relate to personal protection systems against COVID-19 including face masks and methods, systems or devices of managing, regulating and/or filtering airflow during travel on an aircraft, train, or bus.

traducir

The Severity Level and Early Prediction of Covid-19 Using CEDCNN Classifier

NºPublicación: AU2020102631A4 26/11/2020

Solicitante:

A ANBUCHEZIAN DR [IN]
JAIN PARAS DR [IN]
M MADIAJAGAN DR [IN]
M SHAHINA PARVEEN DR [IN]
N PRADEEP DR [IN]
T SUBRAMANI DR [IN]
UDAYAKUMAR SRIDHAR MR [ET]

Resumen de: AU2020102631A4

The Severity Level and Early Prediction of Covid-19 Using CEDCNN Classifier The rapid spread of Coronavirus disease 2019 (COVID-19) has brought doctors, researchers, and data scientists together to find a solution. Scientists are using sophisticated technologies, such as big data analytics, machine learning, and natural language processing for tracking the virus and learning more about it. On the one hand, the excess of stored data has considerably increased the opportunities to interrelate and analyze them. This proposed invention is to predict the severity level and early prediction of COVID-19 using Cross Entropy-based Deep Convolutional Neural Network (CEDCNN) for big data. This invented work is composed of '3' steps, namely, disease prediction, severity level analysis, and early prediction. In the first phase, initially, the dataset is preprocessed, then the important features are extracted from the dataset, and finally, the disease is clustered into positive and predictive using Taxicab Norm K Means (TNKM). In phase 2, the proposed system utilizes CEDCNN for severity analysis, which classifies a high, low, and moderate level. In phase 3, the non-coronavirus data undergoes preprocessing, and then important features are extracted from the dataset. Finally, the potential level of the patient against the coronavirus is predicted by the Mahalanobis Distance Ranking (MDR) method. NCoV19 dataiset Pre- processing Feature Clustering Normializat exrction TNKM OutputClassfiedseeos

traducir

NLP-ARTIFICIAL INTELLIGENCE BASED AUTOMATIC DETECTION OF INFECTION RATE OF PANDEMIC DISEASES (COVID-19)

NºPublicación: AU2020102643A4 26/11/2020

Solicitante:

CHAMAKERI PUNEET H DR DR [IN]
CHINNADURAI VEERA MR [IN]
H D RANJIT MR [IN]
JADHAV JAGANNATH DR [IN]
KHAN RUBINA JAHANGIR MISS [IN]
PATIL ARATI DR [IN]
RAMPURE PRASAD B DR [IN]
RAO SURAPUDI SRINIVASA DR [IN]
SONAVALE AMRUTA P MRS [IN]

Resumen de: AU2020102643A4

NLP-ARTIFICIAL INTELLIGENCE BASED AUTOMATIC DETECTION OF INFECTION RATE OF PANDEMIC DISEASES (COVID-19) Threat of pandemic diseases is emerging in the current era, specifically Covid-19 acting as infectious disease leading to death of huge population in the universe. Involvement of technology is demanded for innovative solutions in various aspects in perspective of pandemic disease. A hope is offered by Artificial Intelligence (AI) which can efficiently prevent, pre-empt and combat the threats of such epidemic infectious disease. Enormous potential is offered by Al concerning public health for revolutionizing healthcare which can provide expansion for accessing health information along with its services which in turn enhances the responsibility of individual to know about their well being and health. Natural language programming (NLP) is one of the subfield of Al aiming to bridge the gap between human language and computer language. Applications of Al are able to determine significance of text by using NLP by which machine is able to identify phrases and keywords related to pandemic disease such that infection rate is determined automatically from huge amount of datasets. NLP focuses on information processing and managing data to infer relationship between featured words in a prominent way. and preprsigPAy ShData Data VanesTesDofDiseasesRelated Data Figure 1. Proposed System of Artificial Intelligence based Detection of Disease Infection Rate onnesnades data itdeon edpEgy ena

traducir

PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES

NºPublicación: WO2020232515A1 26/11/2020

Solicitante:

FIREBRICK PHARMA PTY LTD [AU]

US_2020384016_A1

Resumen de: WO2020232515A1

This invention is directed to methods for prevention of infections by highly pathogenic (HP) viruses by applying to the nasal mucous membranes a topical preparation comprising the broad-spectrum antimicrobial agent povidone-iodine (PVP-I). Said viruses include SARS and MERS Coronaviruses, such as SARS-CoV-2 (which causes COVID-19), Filoviridae such as Ebola Virus (EBOV), Marburg Virus (MARV), Sudan Virus (SUDV), Tai Forest Virus (TAFV) and Bundibugyo Virus (BDBV), pandemic influenza viruses such as H5N1, H5N9, H7N3, H7N7, H9N2 and H1N1, and Arenaviridae that cause Lassa fever, Junin and Machupo, Bunyaviridae that cause Crimean-Congo haemorrhagic fever, Rift Valley Fever, Hantaan haemorrhagic fevers, and Flaviviridae that cause yellow fever, dengue, Omsk haemorrhagic fever, Kyasanur forest disease. The present invention further relates to a method of decreasing secondary infections from a primary HP viral infection, caused by bacteria or fungus such as Mycoplasma pneumoniae, S. aureus, K. pneumoniae, S. pneumoniae, M. catarrhalis, P. aeruginosa, S. pyogenes, or Streptococcus agalactiae.

traducir

HUMAN BETACORONAVIRUS LINEAGE C AND IDENTIFICATION OF N-TERMINAL DIPEPTIDYL PEPTIDASE AS ITS VIRUS RECEPTOR

NºPublicación: EP3741846A2 25/11/2020

Solicitante:

UNIV ERASMUS MED CT ROTTERDAM [NL]
DR SOLIMAN ABDULKHADER FAKEEH HOSPITAL COMPANY [SA]

ES_2790841_T3

Resumen de: EP3741846A2

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

traducir

2 COMPOSITION FOR PREVENTING OR TREATING SARS CORONAVIRUS 2 INFECTION DISEASE

NºPublicación: KR20200131784A 24/11/2020

Solicitante:

SYNTEKABIO CO LTD [KR]

Resumen de: KR20200131784A

본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염; 및 글루카곤 수용체 작용제(glucagon receptor agonist), 위 억제 펩타이드(gastric inhibitory peptide, GIP), 글루카곤-유사 펩타이드 1(glucagon-like peptide 1, GLP-1) 및 글루카곤 수용체/위 억제 펩타이드/글루카곤-유사 펩타이드 1(Glucagon/GIP/GLP-1) 삼중 완전 작용제(glucagon receptors, gastric inhibitory peptide and glucagon-like peptide 1 (Glucagon/GIP/GLP-1) triple full agonist)로 이루어진 군으로부터 선택된 1종 이상;을 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다.

traducir

Rapid viral assay

NºPublicación: US10844442B1 24/11/2020

Solicitante:

BARNHIZER BRET T [US]
FARO JONATHAN P [US]

Resumen de: US10844442B1

The invention provides a method for rapid, highly specific and sensitive detection and quantification of a virus by observing viral substrate binding to its host receptor protein. The invention also provides a method for rapid, highly specific and sensitive detection and quantification of a virus in an individual suspected of being infected with a virus. The invention further provides a test kit for rapid, highly specific and sensitive point-of-care detection of a virus in an individual. The viruses and their host receptor proteins that can rapidly be detected include SARS-CoV-2 and its host receptor protein ACE2. The surprisingly rapid, specific and sensitive method of the invention provides a point-of care test capable of diagnosing individuals suffering from COVID-19 by observation of a color change in the assay, which color change occurs in about five minutes, and which test can be completed by a user in about one hour.

traducir

Methods of Treating Cytokine Storm Infections, Including COVID-19, By Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same

NºPublicación: US2020362044A1 19/11/2020

Solicitante:

INCELLDX INC [US]

Resumen de: US2020362044A1

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

traducir

LIVE IMAGING SYSTEM TO VISUALIZE THE RETRO-TRANSCRIBED VIRAL DNA GENOME

NºPublicación: WO2020229893A1 19/11/2020

Solicitante:

PASTEUR INSTITUT [FR]

Resumen de: WO2020229893A1

A recombinant lentiviral vector comprising a coding sequence for an OR protein fused to a coding sequence for a fluorescent protein or a subunit of a fluorescent protein, and a promoter active in human cells operatively linked to the coding sequences. A recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription. A recombinant eukaryotic cell comprising a genomically integrated DNA copy of the recombinant lentiviral vector. A method of observing lentiviral DNA in a eukaryotic cell, comprising: providing a recombinant eukaryotic cell that produces a fusion protein comprising an OR protein, fused to a fluorescent protein or a subunit of a fluorescent protein; infecting the recombinant eukaryotic cell with a recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription, under conditions sufficient for reverse transcription of the recombinant lentiviral genome comprising an ANCH sequence; allowing the OR protein to bind to the ANCH sequence; and detecting the fluorescent protein or subunit of the fluorescent protein to thereby observe the lentiviral DNA in the eukaryotic cell. This tool can be suitable also for in vivo applications (e.g. humanized mice) as well as for screening of new antiretroviral compounds. The HIV-1 ANCHOR system can be extended to the study of other viruses or for the screening of antiviral compounds, e.g. against SARS-CoV2.

traducir

METHOD OF PREDICTING THE COURSE OF PNEUMONIA IN COVID-19 BASED ON THE COLLATION THE RESULTS OF DMS AND MSCT OF LUNGS

NºPublicación: RU2736341C1 16/11/2020

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE \u00ABNATSIONALNYI MEDITSINSKII ISSLEDOVATELSKII TSEN [RU]

Resumen de: RU2736341C1

FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to radiation diagnostics, and can be used for prediction of pneumonia caused by SARS-CoV-2 virus. Performing DMS and MSCT of lungs with interval of not more than 24 hours with determination of severity of pulmonary tissue involvement (SDMS) and (SMSCT). Ultrasonic scanning of the lungs is performed in 20 or 16 zones presented in Figures 1 and 2 respectively. Areas with marked interstitial changes and/or consolidations are identified. Marked interstitial changes are determined in the presence of two and more merging B-lines, and/or one or more B-lines not merging with each other, echogenicity of which corresponds to or is higher than the echogenicity of the pleural line and has thickness of 3 mm and more at the point of separation from the pleural line. Based on the obtained data, the lesion area is determined by formula: S=n/N*100, where S is area of pulmonary involvement in %, n is number of zones with detected changes, N is total number of zones on which lungs were separated in DMS. Degree of severity of pulmonary tissue injury is evaluated by DMS (SDMS) and MSCT (SMSCT): if a lesion of up to 25 % of lung area is considered to be "1" degree; from 25 to 50 % "2" degree is determined; from 50 to 75 % "3" degree is determined; from 75 to 100 % "4" degree is determined. Obtained values of SDMSand SMSCTare compared. If SDMS> SMSCT, the negative dynamics of the clinical course is predicted for 2-5 days after DMS and

traducir

PEPTIDES HAVING PROTEASE ACTIVITY FOR USE IN THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION

NºPublicación: US2020353060A1 12/11/2020

Solicitante:

ENZYMATICA AB [SE]

KR_20200107958_A

Resumen de: US2020353060A1

The present invention provides a polypeptide having protease activity for use in the treatment or prevention of coronavirus infection in a mammal. In particular, the invention relates to treatment or prevention of a coronavirus infection in a human, using trypsins.

traducir

EARLY COVID PREDICTION: NEURO FUZZY MULTI-LAYERED DATA CLASSIFIER

NºPublicación: AU2020102448A4 12/11/2020

Solicitante:

HARI KRISHNA T DR [IN]
KALLAM SURESH DR [IN]
KUMAR MADAPURI RUDRA DR [IN]
PRASANTHI B MS [IN]
RAMANA KADIYALA DR [IN]
SENTHIL MAHESH P C DR [IN]
SURYA NARAYANA G DR [IN]

Resumen de: AU2020102448A4

EARLY COVID PREDICTION: NEURO FUZZY MULTI-LAYERED DATA CLASSIFIER Abstract Coronavirus disease (COVID-19) is a harmful disease caused from new SARS-CoV-2 virus. COVID-19 disease includes the symptoms such as cold, cough, fever and difficulty in breathing. COVID-19 has affected many countries and their spread in world has put humanity at risk. Due to increasing number of cases and their stress on administration as well as health professionals, different prediction techniques were introduced to predict the corona virus disease existence in patients. However, the accuracy was not improved and time consumption was not minimized during the disease prediction. In order to address these problems, Least Square Regressive Gaussian Neuro Fuzzy Multi-Layered Data Classification (LSRGNFM-LDC) Technique is introduced in this article. LSRGNFM-LDC Technique performs efficient COVID prediction with better accuracy and lesser time consumption through feature selection and classification. Deming Least Square Regressive Feature Selection process is carried out for selecting the most relevant features through identifying the line of best fit. After the feature selection process, the data classification is carried out using neuro-fuzzy classifier with help of fuzzy if-then rules for performing prediction process. Finally, the patient data is predicted as the higher risk patient data, medium risk patient data or higher risk patient data in more accurate manner with higher accuracy and lesser time

traducir

A medicine for treating coronavirus-2 infection

NºPublicación: AU2020102463A4 12/11/2020

Solicitante:

DIAO BO [CN]
LIU YUEPING [CN]

Resumen de: AU2020102463A4

The invention discloses a medicine for treating coronavirus-2 infection. The invention finds that T cells in COVID-19 patients is reduced and depleted finally, indicating that cytokines such as IL-10, IL-6, TNF-a may directly mediate reduction of T cells. Therefore, ICU patients need new treatment measures, and may even high-risk patients with low T cells count require early preventive treatment.

traducir

HMGB1 ANTAGONIST

Nº publicación: WO2020227603A1 12/11/2020

Solicitante:

THE FEINSTEIN INSTITUTES FOR MEDICAL RES [US]

US_2021000908_A1

Resumen de: WO2020227603A1

The present invention is related to HMGB1 antagonists, and in particular, HMGB1 tetramer peptidomimetics which have been stabilized with at least one azatide linkage, such as K883 such as K883 and to pharmaceutical compositions comprising HMGB1 antagonists such as K883. The present invention is also related to the use of HMGB 1 antagonists such as K883 to treat a human for e.g. an autoimmune or inflammatory disease or condition, for severe sepsis, for ALI, for influenza, for SARS-CoV-2, for a SARS virus, for neuropathic pain or for diabetic peripheral neuropathy.

traducir

previousPage Página2 de 11 nextPage por página

punteroimgVolver